Pharmaceuticals, Biotechnology and Life Sciences
In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.
Avacta said that Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.
T G4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene’s proprietary myvac® platform with NEC’s cutting-edge…
Abivax said Thursday that ABX464 inhibits replication of SARS-CoV-2 in an in vitro reconstituted human respiratory epithelium model, as assessed by Transepithelial electrical resistance and RTqPCR.
Boehringer Ingelheim has bought Northern Biologics Inc., a wholly owned subsidiary of Northern LP, whose programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim’s position in cancer immunology,
“When Sarclisa was added to standard-of-care treatment carfilzomib and dexamethasone in this phase 3 trial, results clearly demonstrated a significant reduction in risk of disease progression or death, ” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi.
Seattle Genetics gets first approval for Tukysa outside of the U.S., Switzerland’s first approval under FDA initiative project orbis.
Neurocrine Biosciences has exercised its option to license the global rights to Idorsia’s ACT-709478, as it plans to initiate a Phase 2 study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.
Sterling Pharma has announced a partnership with Accord Healthcare to secure the UK supply chain for Hydroxychloroquine (HCQ), a medication currently under investigation for the prevention and treatment of COVID-19.
RedHill Biopharma bagged approval from USFDA for its Investigational New Drug (IND) application for a Phase 2a clinical study to test its investigational drug, opaganib in patients with confirmed moderate-to-severe SARS-CoV-2 infection (the cause of COVID-19).